

**Alaska Medicaid Pharmacy and Therapeutics Committee
Meeting January 18, 2019**

Frontier Building, 3601 C Street; Room **890/896**

Agenda

Public Call in: 1.800.315.6338. Access code **24251#**

1. **Call to Order – Chair** **8:00 am**
2. **Roll Call** **8:05 am**
3. **Public Comment**, including health care professionals

The Department’s methods for class review are to better utilize the time of the P&T Committee. Classes shown in **Red*** and **Blue**** are classes where new information exists and industry testimony will be taken. Classes shown in **Green** are classes where no significant changes have been noted and no industry testimony will be taken.

*New information includes: *new drugs or **new indications, new warnings, new head to head clinical evidence.*

4. Class review, discussion & vote.

AK Treatment Class	Drug Class	Status
Respiratory	COPD Agents	RED**
	Glucocorticoids, Inhaled, Single Entity	BLUE**
	Glucocorticoids, Inhaled, Combination	RED**
	Beta Agonists Bronchodilators, Long	GREEN
	Beta Agonists Bronchodilators, Short	GREEN
Allergy	Epinephrine, Self-Injected	BLUE**
	Intranasal Rhinitis Agents	GREEN
	Leukotriene Modifiers	GREEN
	Antihistamines, Minimally-Sedating	GREEN
Immunological	Cytokine & CAM Antagonists, Non-GI Indications	RED**
	Immunosuppressants, Oral	BLUE**
Dermatological	Antipsoriatics Topical	GREEN
	Immunomodulators, Atopic Dermatitis	BLUE**
	Topical Steroids Low Potency	GREEN
	Topical Steroids Medium Potency	GREEN
	Topical Steroids High Potency	BLUE**
	Topical Steroids Very High Potency	BLUE**
	Acne, Topical	BLUE**
Ophthalmics	Ophthalmic, Allergic Conjunctivitis	GREEN
	Ophthalmic, Antibiotics	GREEN
	Ophthalmic, Antibiotics-Steroid Combination	GREEN
	Ophthalmic, Anti-inflammatory	RED**
	Ophthalmic, Glaucoma Agents	RED**
	Ophthalmic, Immunomodulators	BLUE**

7. **Break as needed** – 15 minutes
8. **Review minutes** from **November 2018** meeting
9. **Comments from Committee Members or Chair**
10. **Adjourn**

Any pharmaceutical manufacturer may submit unsolicited material related to the agenda items by utilizing the Clinical Submission form. Clinical Submissions will be accepted until January 3, 2019 at 4:00pm AK local time. Forms may be found at: http://dhss.alaska.gov/dhcs/Pages/pdl/download_pdl.aspx.

Any member of the public, including health care professionals, may submit unsolicited material related to the agenda items by sending an email to erin.narus@alaska.gov or via mail to 4501 Business Park Blvd, Bldg L, Anchorage, AK 99503. Submissions should be received no later than January 8, 2019 to allow inclusion in the meeting.

Next Meeting Date: April 19, 2019